Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Semaglutide Quick Facts: Drug Class: GLP-1 receptor agonist Brand Names: Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral) FDA Approval: Ozempic approved 2017, Wegovy approved 2021 Manufacturer: Novo Nordisk Dosing: Once weekly injection, starting at 0.25 mg, maximum 2.4 mg Clinical Trial Name: STEP trials (Semaglutide Treatment Effect in People with obesity) Average Weight Loss: 10-15% of body weight over 68 weeks Tirzepatide Quick Facts: Drug Class: Dual GIP/GLP-1 receptor agonist Brand Names: Mounjaro (diabetes), Zepbound (weight loss) FDA Approval: Mounjaro approved 2022, Zepbound approved 2023 Manufacturer: Eli Lilly Dosing: Once weekly injection, starting at 2.5 mg, maximum 15 mg Clinical Trial Name: SURMOUNT trials (Study to evaluate tirzepatide in obesity or overweight) Average Weight Loss: 15-22% of body weight over 72 weeks Primary Difference: The main distinction is that semaglutide activates only GLP-1 receptors, while tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors
Im definitely losing weight, it took several days to start feeling the effects but it does work
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons
If you've done your research, understand the regulatory realities, and believe the program aligns with your needs, HealthRX provides a pathway to explore medically supervised weight loss heading into 2026
Table of Contents How GLP-1 Medications Work in the Body Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to manage type 2 diabetes and, more recently, obesity
US$ 29.56
US$ 28.18
US$ 25.16
US$ 28.43
US$ 28.87
US$ 25.67
